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perfusion was evaluated by myocardial perfusion grade (MBG). All the
patients were divided into good perfusion group (MBG 2, n¼137) and
poor perfusion group (MBG 1, n¼31) according to post intervention
MBG. The MPV, white blood cell (WBC) count, and so on were
compared. And the correlative factors were analyzed to ﬁnd out the
predictors of myocardial perfusion post PPCI.
RESULTS The MPV (11.21.4 fL vs. 9.51.3 fL, P <0.001) and WBC
count (11.11.0 109/L vs. 10.11.3 109/L, P <0.001) were higher in
poor perfusion group comparing with the good perfusion group.
Multivariate logistic regression analysis showed that MPV (OR 0.42,
95% CI 0.28-0.61, P <0.001) and WBC count (OR 0.59, 95% CI 0.39-
0.90, P ¼0.015) were the predictors of poor myocardial perfusion after
PPCI. MPV was also correlated with post PPCI MBG (r ¼ -0.607,
P<0.001) and LVEF (r ¼ -0.621, P <0.001).
CONCLUSIONS In STEMI patient receiving PPCI, higher pre-inter-
vention MPV and WBC count means poor myocardial perfusion, and
higher MPV also indicates worse left ventricular systolic function post
PPCI.
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A new cooperative approach in treatment of acute myocardial
infarction in China
Jinchuan Yan
Afﬁliated Hospital of Jiangsu University
OBJECTIVES Acute myocardial infarction (AMI) is the most serious
type of coronary heart disease that affect the life and health of people,
but < 30% of all of the patients with AMI have been treated effectively
and timely in China. Delayed treatment has been considered as a
leading cause of death and severe outcomes. This study aimed to
evaluate a new regional cooperative emergency model in improving
the ﬁrst medical contact-to-balloon time and the therapeutic effects
on patients with ST-elevation myocardial infarction (STEMI).
METHODS A new regional cooperative emergency model was estab-
lished in some regions of Zhenjiang, Jiangsu province in China. A
retrospective analysis of 458 STEMI patients before and after the
model used in these regions was performed. Patients were divided
into two groups in terms of before or after the regional cooperative
rescue model used: model group (n¼285) and control group (n¼173).
The ﬁrst medical contact-to-balloon (FMC-to-B) time, door-to-balloon
(D-to-B) time, referral time, cardiac function, mean cost, days of
hospitalization, and major adverse cardiac events (MACE) were
analyzed.
RESULTS The mean FMC-to-B time, D-to-B time and referral time of
the model group were 97  20, 22  8, 61  17 min, respectively, these
parameters were signiﬁcantly lower than the corresponding indexes
of the control group (211  27, 105  14, 101  19 min). Six months after
the patients were discharged from the hospital, the left ventricular
ejection fraction (LVEF) of the model group increased but left ven-
tricular end-diastolic dimension (LVED) was decreased when
compared with control group. These results also showed that mean
costs (43813.0  2731.0 vs 50471.0  5264.0 CNY) and days of hospi-
talization (7.85  3.15 vs 11.02  4.06 days) were reduced. The inci-
dence rate of MACE in the model group was 8.2%, which was lower
than the rate of 16.8% in the control group.
CONCLUSIONS Regional cooperative emergency model may decrease
the FMC-to-B time, which could improve the cardiac function, ther-
apeutic effect on patients with AMI, and decrease ﬁnancial burden of
patients.
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Platelet aggregation inﬂuenced by the loading-dose of multiple
anti-platelet therapy in patients with acute myocardial infarction
Long Peng,1 Xixiang Tang,2 Yanting Luo,1 Jinlai Liu1
1Department of Cardiology, the Third Afﬁliated Hospital, Sun Yat-sen
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OBJECTIVES Due to the severity of acute myocardial infarction (AMI)
and cardiovascular interventions, many patients should be prescribed
multiple anti-platelet therapy to reduce platelet aggregation. We
aimed to explore the inﬂuence of the loading-dose of multiple
anti-platelet drugs on the inhibition of platelet aggregation in patients
with AMI.
METHODS The present study included 84 patients who were initially
diagnosed with AMI. Patients were divided into 3 groups randomly:AC group (aspirin 0.3g plus clopidogrel 0.3g), ATG group (aspirins 0.3g
plus ticagrelor 0.18g), and ACTF group (triple therapy with aspirins
0.3g, clopidogrel 0.3g and tiroﬁban 0.15ug/kg/min). Adenosine
diphosphate(ADP)-induced platelet aggregation was measured using
the multiplate analyzer at the time of initial diagnose of AMI, 2 hours
after taking loading-dose of anti-platelet therapy, and the second
morning.
RESULTS There were no signiﬁcant differences in demographic
characteristics among groups, including age, risk factors and sex. In
the ADP-induced platelet aggregation ratio, there were not statisti-
cally signiﬁcant among groups at the time of initial diagnose of AMI.
However, there was signiﬁcant difference between before and after
the administration of anti-platelet drugs (53.3%11.2% vs 27.9%
8.5%, p<0.05) in all patients. The platelet aggregation ratio of triple
therapy groups was signiﬁcantly lower than dual anti-platelet ther-
apy, both at the time of 2h after administration drugs and the second
morning(14.3%6.3% vs 23.5%9.4%, p<0.05; 16.4%8.5% vs 33.5%
9.4%). Compared with AC group, ATG group had a signiﬁcantly lower
platelet aggregation ratio at the time of 2 hours after administer drugs
(26.4%7.8% vs 20.6%4.5%, p<0.05). There were no signiﬁcant
differences between AC group and ATG group at the second morning
(32.5%6.4% vs 34.5%7.3%, p¼0.3).
CONCLUSIONS Addition tiroﬁban to conventional dual anti-platelet
therapy can reduce drastically platelet aggregation ratio for the pa-
tients with AMI. Compared to aspirin combination with clopidogrel,
aspirin plus ticagrelor had better inhibiting effect in 2 hours after
administration.
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Peripheral blood based discrimination of Coronary Heart Disease from
healthy people by genome-wide gene expression proﬁling in
Chinese Han people
Lin Fan,1 Heyu Meng,2 Fanbo Meng1
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OBJECTIVES The polygenic inheritance and the dependence on
environmental factors pose a challenge for the diagnosis and treat-
ment of coronary heart disease (CHD). We hypothesized that a mo-
lecular diagnostic assay using easily accessible peripheral blood
would greatly assist in the screening and diagnosis of CHD. In order to
validate this a microarray analysis was carried out, the results indi-
cated that there were some genes had differential expression. We
discussed the function of these differential genes in the process of the
occurrence and development of CHD and further evaluated their
diagnostic potential in CHD.
METHODS A total of 26 subjects (n¼26) were recruited in this study
including 13 CHD and 13 healthy people. The total mRNA of the sub-
jects were isolated from leukocyte in the peripheral blood within 4
hours after collection, and were reversed-transcribed to cDNAs as
soon as possible. We constructed 2 pools of 3 subjects (3 CHD and 3
healthy people) for microarray screening with Affymetrix GeneChip
Scanner 3000 to discover new biomarkers and candidate genes. The
results were analyzed with SAM, GO, KEGG. The other samples were
used for RT-PCR to conﬁrm the microarray on the next step.
Randomly selected three candidate genes from the results of micro-
array for RT-PCR: CYP4F3 acted as up-regulated group, IL13RA1 acted
as normal expression group, MED6 acted as down-regulated group.
The results of RT-PCR was analyzed by 2-DDCt method.
RESULTS The results of microarray were analyzed by Affymetrix
Expression Console Software. With the choice criterion of p0.05,
logFC1 or logFC-1, there were 300 differential genes being selected,
among them 30 genes had over expression and 270 genes had low
expression. Analyzed by GO showed these 300 genes belonged to 105
cellular components, and involved in 295 biological processes and
participated in the regulation of 212 molecular functions. Analyzed by
KEGG showed that these genes took part in 75 gene pathways. The results
of RT-PCR analyzed with 2-DDCt method showed that compared to healthy
people, the expression of CYP4F3 gene was 2.06  0.57 (p¼0.004), the
expression of IL13RA1 gene was 0.96 0.05 (p¼0.870), and the expression
of MED6 gene was 0.62  0.12 (p¼0.002). All the results obtained from
RT-PCR were in accordance with the results of microarray.
CONCLUSIONS The microarray can be used as the foundation of
exploring the pathogenic gene for coronary heart disease, and the
differential expression of CYP4F3 or MED6 may take effect on the
process of the occurrence and development of coronary heart disease.
It can be conjectured that these ﬁndings may serve to identify new
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stimulate further studies to establish a prediction tool for progression
of coronary heart disease.
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Association of serum sSema4D level with coronary atherosclerotic disease
Long Kuang, Liangping Zhao, Jianchang Chen, Weiting Xu
Department of Cardiology, Second Afﬁliated Hospital, Soochow
University
OBJECTIVES Recent studies showed that sema4D has signiﬁcant role
in atherosclerosis and thrombosis. Elevation in Sema4D level is
considered to be a novel risk factor for thrombotic disease. Being a
research highlight these years, there has been little real-world clinical
studies on Sema4D so far.
METHODS 1. 158 consecutive inpatients from the department of car-
diology in the 2nd afﬁliated hospital of Soochow University was
included in this study. The sum consist of stable 53 cases with angina
pectoris, 105 with Acute Coronary Syndrome. There were 59 subjects
in the healthy control group.
2. Enzyme-linked immunosorbent assay was utilized to test the
serum level of Sema4D.
3. All subjects underwent coronary angiography after admission,
diameter method was used to quantify the extent of coronary arterial
stenosis, which was then put into calculation with Gensini Score.
4. According to cutoff of sSema4D derived from receiver operator
curve, patients were divided into high sSema4D group (n¼95) and low
sSema4D group (n¼63). Follow-up of major adverse cardiovascular
events each 3 months was carried out within one year after discharge.
Survival analysis between both groups was performed using Kaplan-
Meier Method.
RESULTS 1. Coronary atherosclerotic disease group had signiﬁcantly
higher level of serum sSema4D compared with control (9.232.64 vs
3.931.39ng/mL, P<0.001). Moreover, patients with acute coronary
syndrome had elevated serum sSema4D level compared with those
with stable coronary atherosclerotic disease(10.132.54 vs
7.461.80ng/mL, P<0.001).
2. Patients with Gensini score over 40(11.492.73ng/mL) showed
signiﬁcantly increased serum sSema4D level compare with those
with Gensini score under 20(7.632.16ng/mL) or 20 through
40(9.531.97ng/mL).(P<0.05)
3. Serum sSema4D was positively correlated with Gensini Score
(r¼0.662, P<0.001) according to linear correlation analysis
4. Multivariate logistic regression analysis revealed that serum
sSema4D was an independent risk factor for coronary atherosclerotic
disease(OR¼7.18, 95% CI: 3.38w15.23, P<0.001) as well as for major
adverse cardiovascular events(OR¼3.178, 95% CI: 1.025w9.849,
P<0.05).
5. In patients from coronary atherosclerotic disease group, subjects
with increased level of sSema4D showed decreased major adverse
cardiovascular events-free survival rate compared with those with
relatively lower level of sSema4D(log-rank test c2¼15.149, P<0.01).
CONCLUSIONS 1. Serum sSema4D was increased in coronary athero-
sclerotic disease and even more elevated in acute coronary syndrome.
2. The positive correlation between sSema4D and Gensini score in-
dicates that sSema4D level can reﬂect the severity of coronary arterial
lesion.
3. sSema4D can be used to predict the prognosis of coronary
atherosclerotic diseases it was found to be an independent risk factor
for major adverse cardiovascular events.
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ADP-induced platelet-ﬁbrin clot strength: prediction of major bleeding
and dyspnea side effects in ticagrelor treated Chinese ACS patients
Tong Yin, Xuyun Wang, Jia Liu, Yundai Chen
Department of Cardiology, General Hospital of Chinese People’s
Liberation Army, Beijing, China
OBJECTIVES Ticagrelor provides more potent platelet inhibition than
clopidogrel, however, enhanced efﬁcacy of ticagrelor increases the
risk of bleeding and dyspnea side effects. This study sought to display
the role of ADP-induced platelet-ﬁbrin clot strength for the prediction
of bleeding and dyspnea side effect in ticagrelor treated Chinese acute
coronary syndrome (ACS) patients.
METHODS Consecutive Chinese-Han patients with ACS who received
maintenance dose of ticagrelor (90 mg, bid) and aspirin (100mg, qd)
were recruited from General Hospital of Chinese People’s LiberationArmy. After 5 days ticagrelor maintenance treatment, ADP-induced
platelet-ﬁbrin clot strength (MAADP) measured by thrombelastography
(TEG) were recorded. Pre-speciﬁed cutoffs of MAADP with consensus
for high on-treatment platelet reactivity (HTPR) and low on-treatment
platelet reactivity (LTPR) to ADP associated with ischemia and
bleeding events were applied for evaluation. Bleeding events ac-
cording to TIMI criteria and ticagrelor related dyspnea side effect were
recorded after a follow-up of 3 months.
RESULTS Overall, 532 ACS patients (Male: 72.56%, Age:6011 years)
under ticagrelor maintenance treatment were recruited. Antiplatelet
responsiveness measured by TEG was available in 176 patients. After 5
days’ ticagrelor maintenance treatment, the value of MAADP was
(21.2712.07)% on average (ranged from 4.8% to 72.9%). With the pre-
speciﬁc cutoffs for HTPR (TEG-MAADP>47mm) and LTPR (TEG-
MAADP<31mm), 7 patients (3.98%) were identiﬁed as HTPR and143
patients (81.25%) as LTPR. Among 89 patients who were followed up
for 3 months, bleeding events occurred in 43 patients (48.31%), with
major bleeding in 3 patients (3.37%), and minor bleeding in 40 pa-
tients (44.94%). All patients with major bleeding events were classi-
ﬁed as LTPR. The distribution of patients with minor bleeding events
was 3 (42.86%) in HTPR and 27 (18.88%) in LTPR, respectively. Tica-
grelor related dyspnea side effect occurred in 22 patients (24.71%),
and all of them were classiﬁed as LTPR.
CONCLUSIONS ADP-induced platelet-ﬁbrin clot strength (MAADP) as
measured by TEG could predict major bleeding and dyspnea side ef-
fects in ticagrelor treated ACS patients.
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Treatment with enhanced external counterpulsation improves cardioankle
vascular index in old patients with atherosclerotic cardiovascular diseases
Mingzhong Zhao, Yong Cheng, Qingru Yuan, Juan Yu, Jiao Zhou
Heart Center, Zhengzhou Ninth People’s Hospital, Zhengzhou 450053,
P.R. China
OBJECTIVES Enhanced external counterpulsation (EECP) therapy
enhances coronary perfusion, lowers symptom episodes and improves
quality of life in patients with atherosclerotic cardiovascular diseases
(ASCVD). However, there is little understanding about the impact of
EECP therapy on arteriosclerosis in this population. Our aim was to
investigate the effects of EECP on arterial stiffness which was iden-
tiﬁed by a novel markerdcardioankle vascular index(CAVI), and
evaluate what factors were cruel to inﬂuence the improvement of
CAVI following EECP treatment in old patients with ASCVD.
METHODS One hundred and three old individuals(mean age:70.3 9.7
years) who were diagnosed with ASCVD enrolled consecutively in the
study from Mar. 2014 to Oct. 2014. A prospective observational lon-
gitudinal study was conducted to investigate the changes of arterial
wall stiffness assessed using CAVI after 35 sessions of 1-hr daily EECP
treatment in these patients.
RESULTS Compared with baseline values, LVEF value increased and
plasma concentrations of NT-proBNP, hs-CRP, and homocysteine
signiﬁcantly decreased at the end of 35th sessions of EECP treat-
ment, respectively. After 17th session of EECP treatment, both left
CAVI(CAVI-L) and right CAVI(CAVI-R) were lower than those at
baseline, respectively(CAVI-L : 8.090.93 vs 8.670.96; CAVI-R:
8.171.16 vs 8.981.23; all P<0.05). After 35th session of EECP
treatment, both CAVI-L and CAVI-R decreased signiﬁcantly
compared to baseline, respectively (CAVI-L : 7.450.87 vs 8.670.96;
CAVI-R: 7.621.26 vs 8.981.23; all P<0.001). There was also sig-
niﬁcantly difference for CAVI values between 17th and 35th ses-
sion of EECP treatment (CAVI-L : 7.450.87 vs 8.090.93; CAVI-R:
7.621.26 vs 8.171.16 ;all P<0.05). Subgroup analysis showed that
old patients with multimorbidity factors4 had a higher value of
CAVI than those with multimorbidity factors3, and the former group
had more signiﬁcant decreases in CAVI values following either 17th
sessions or 35th sessions of EECP therapy when compared to the latter
group, respectively (p < 0.01).
CONCLUSIONS Besides increasing LVEF, as well as lowering serum
levels of NT-proBNP, Hs-CRP, homocysteine, EECP therapy improves
arterial stiffness by reducing the CAVI values in old patients with
ASCVD, especially in those with multimorbidity factors4. Multi-
morbidity factors are signiﬁcantly associated with the degrees of al-
terations in CAVI parameter derived from EECP treatment. The study
implies EECP treatment is beneﬁcial for artery stiffness in old patients
with ASCVD. The improvement of arteriosclerosis is coincident with
cardiac function changes and inﬂammatory reactions control,
providing further insight into the potential mechanisms of EECP-
mediated amelioration in atherosclerosis.
